MY136761A - Oxazol derivatives - Google Patents

Oxazol derivatives

Info

Publication number
MY136761A
MY136761A MYPI20021726A MYPI20021726A MY136761A MY 136761 A MY136761 A MY 136761A MY PI20021726 A MYPI20021726 A MY PI20021726A MY PI20021726 A MYPI20021726 A MY PI20021726A MY 136761 A MY136761 A MY 136761A
Authority
MY
Malaysia
Prior art keywords
oxazol
derivatives
oxazol derivatives
compounds
diabetes
Prior art date
Application number
MYPI20021726A
Other languages
English (en)
Inventor
Alfred Binggeli
Markus Boehringer
Uwe Grether
Hans Hilpert
Hans-Peter Maerki
Markus Meyer
Peter Mohr
Fabienne Ricklin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MY136761A publication Critical patent/MY136761A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI20021726A 2001-05-15 2002-05-13 Oxazol derivatives MY136761A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01111745 2001-05-15

Publications (1)

Publication Number Publication Date
MY136761A true MY136761A (en) 2008-11-28

Family

ID=8177436

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20021726A MY136761A (en) 2001-05-15 2002-05-13 Oxazol derivatives

Country Status (38)

Country Link
US (1) US6642389B2 (OSRAM)
EP (1) EP1392295B1 (OSRAM)
JP (2) JP4330883B2 (OSRAM)
KR (1) KR100654516B1 (OSRAM)
CN (1) CN100356917C (OSRAM)
AR (1) AR035892A1 (OSRAM)
AT (1) ATE327753T1 (OSRAM)
AU (1) AU2002342244B2 (OSRAM)
BG (1) BG66316B1 (OSRAM)
BR (1) BRPI0209821B1 (OSRAM)
CA (1) CA2445145C (OSRAM)
CY (1) CY1105160T1 (OSRAM)
CZ (1) CZ20033037A3 (OSRAM)
DE (1) DE60211891T2 (OSRAM)
DK (1) DK1392295T3 (OSRAM)
EC (1) ECSP034848A (OSRAM)
EG (1) EG25755A (OSRAM)
ES (1) ES2264482T3 (OSRAM)
GT (1) GT200200085A (OSRAM)
HR (1) HRP20030889B1 (OSRAM)
HU (1) HU230224B1 (OSRAM)
IL (2) IL158589A0 (OSRAM)
JO (1) JO2282B1 (OSRAM)
MA (1) MA27025A1 (OSRAM)
ME (1) ME01310B (OSRAM)
MX (1) MXPA03010435A (OSRAM)
MY (1) MY136761A (OSRAM)
NO (1) NO333833B1 (OSRAM)
NZ (1) NZ529033A (OSRAM)
PA (1) PA8544901A1 (OSRAM)
PE (1) PE20021152A1 (OSRAM)
PL (1) PL208074B1 (OSRAM)
PT (1) PT1392295E (OSRAM)
RU (1) RU2278859C2 (OSRAM)
SI (1) SI1392295T1 (OSRAM)
SK (1) SK287842B6 (OSRAM)
WO (1) WO2002092084A1 (OSRAM)
ZA (1) ZA200308538B (OSRAM)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
KR100545507B1 (ko) * 2000-05-26 2006-01-24 니뽄 신야쿠 가부시키가이샤 복소환 유도체
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
PL208074B1 (pl) * 2001-05-15 2011-03-31 Hoffmann La Roche Pochodne oksazolu, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie pochodnych oksazolu
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
JP2005504043A (ja) * 2001-08-10 2005-02-10 パラチン テクノロジーズ インク． 生物学的に活性な金属ペプチド類のペプチド模倣体類
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
JP2005528346A (ja) 2002-02-25 2005-09-22 イーライ・リリー・アンド・カンパニー ペルオキシソーム増殖因子活性化受容体調節物質
DK1537091T3 (da) * 2002-08-30 2010-11-08 Hoffmann La Roche Hidtil ukendte 2-arylthiazolforbindelser som PPAR alpha- og PPAR gamma-agonister
TWI343915B (en) 2002-10-07 2011-06-21 Hoffmann La Roche Chirale ppar agonists
AU2003302111A1 (en) * 2002-11-15 2004-06-15 Cadila Healthcare Limited Substituted aralkyl derivatives
DE60323130D1 (de) * 2002-11-25 2008-10-02 Hoffmann La Roche Indolderivaten
US7268157B2 (en) * 2002-11-26 2007-09-11 Shenzhen Chipscreen Biosciences, Ltd. Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity
FR2849849B1 (fr) * 2003-01-13 2006-08-04 Merck Sante Sas Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7262303B2 (en) 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
JP2007509998A (ja) 2003-11-05 2007-04-19 エフ．ホフマン−ラ　ロシュ　アーゲー Ｐｐａｒ活性化剤としてのベンズ環付加された化合物
KR20080042188A (ko) * 2003-11-05 2008-05-14 에프. 호프만-라 로슈 아게 Ｐｐａｒ 작용제로서 페닐 유도체
WO2005056536A1 (en) * 2003-12-10 2005-06-23 Ranbaxy Laboratories Limited Antidiabetic agents which exhibit activity against ppar
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
CA2564563C (en) 2004-05-03 2011-07-05 F. Hoffmann-La Roche Ag Indolyl derivatives as liver-x-receptor modulators
CN100344618C (zh) * 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物
CN100436430C (zh) * 2004-05-24 2008-11-26 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的烷酰基取代的酪氨酸衍生物
WO2006108491A1 (en) * 2005-04-11 2006-10-19 Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg Improved process for preparing oxazole nitriles
US20060241073A1 (en) * 2005-04-20 2006-10-26 Wanders Ronaldus J A Means and methods for counteracting fatty acid accumulation
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
KR100847780B1 (ko) * 2006-10-26 2008-07-23 재단법인서울대학교산학협력재단 2-에톡시프로피온산 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 당뇨병 예방 및 치료제
GB2460784A (en) * 2007-03-07 2009-12-16 Dong A Pharmtech Co Ltd Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators,method of the same,and pharmaceutical composition
PT2100604E (pt) * 2008-03-10 2012-07-24 Nestec Sa Ácidos dicarboxílicos de cadeia média e os seus derivados e doenças metabólicas
AU2009246626A1 (en) * 2008-05-15 2009-11-19 Merck Sharp & Dohme Corp. Oxazolobenzimidazole derivatives
KR101285520B1 (ko) 2008-12-23 2013-07-17 에프. 호프만-라 로슈 아게 만성 질병을 가진 환자의 진단 또는 치료 지원을 위한 구조화된 테스팅 방법 및 그 디바이스
AU2010206249B2 (en) * 2009-01-23 2015-07-09 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising aleglitazar
CN101805337B (zh) * 2009-02-13 2012-05-23 天津药物研究院 一类含脯氨酸和异恶唑骨架的化合物、其制备方法和用途
US8450496B2 (en) 2009-03-24 2013-05-28 Hoffman-La Roche Inc. Process for the preparation of propionic acid derivatives
NZ600273A (en) 2009-12-07 2014-03-28 Hoffmann La Roche Process for the preparation of propionic acid derivatives
CN102351852B (zh) * 2011-08-23 2014-06-18 上海交通大学 苯并呋喃类化合物及其制备方法、用途
WO2013181384A1 (en) 2012-05-31 2013-12-05 Ratiopharm Gmbh Solid state forms of aleglitazar sodium
CN104619689B (zh) * 2012-09-12 2017-08-08 霍夫曼-拉罗奇有限公司 (S)‑2‑甲氧基‑3‑{4‑[2‑(5‑甲基‑2‑苯基‑噁唑‑4‑基)‑乙氧基]‑苯并[b]噻吩‑7‑基}‑丙酸的固体形式及其盐的固体形式
CN109588042A (zh) 2015-11-18 2019-04-05 豪夫迈·罗氏有限公司 用于治疗糖尿病肾病的阿格列扎
WO2018002215A1 (en) 2016-06-30 2018-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cardiomyopathies
WO2020156683A1 (en) 2019-02-01 2020-08-06 F. Hoffmann-La Roche Ag Aleglitazar for use in the treatment or prevention of major adverse cardiac events
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
JP2024532807A (ja) * 2021-08-13 2024-09-10 アレバンド ファーマシューティカルズ（ホンコン）リミテッド 重水素化化合物
JP2025538159A (ja) 2022-11-08 2025-11-26 ジェンフィット 肝不全の治療において使用するためのｐｐａｒ－アルファ／ガンマアゴニスト
CN118480034B (zh) * 2023-02-13 2025-02-11 礼邦医药(香港)有限公司 氘代化合物的晶型或盐

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4011326A (en) 1975-07-29 1977-03-08 Merck & Co., Inc. 2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
RU2032677C1 (ru) * 1992-05-05 1995-04-10 Бристоль-Мейерз Сквибб Компани Производные оксазола
EP0648212B1 (en) 1992-07-03 2001-10-24 Smithkline Beecham Plc Benzoxazole and benzothiazole derivatives as pharmaceutical
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
DE4317320A1 (de) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
ZA9711051B (en) 1996-12-10 1999-06-09 Bristol Myers Squibb Co Benzodioxole benzofuran dihydrobenzofuran and benzodioxane melatonergic agents
DE19711616A1 (de) * 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Herstellung von Thiazolidindionen
US6121397A (en) 1997-07-14 2000-09-19 Xerox Corporation Polymerization processes using oligomeric compound, monomer and surfactant
HN1998000118A (es) 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
ES2200248T3 (es) 1997-09-19 2004-03-01 Ssp Co., Ltd. Derivados de acudi fenilpropionico sustituido en alfa y medicamento que los contienen.
WO1999008501A2 (en) 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
EP1078923B1 (en) 1999-08-02 2006-03-08 F. Hoffmann-La Roche Ag Process for the preparation of benzothiophene derivatives
EA200300286A1 (ru) * 2000-08-23 2003-08-28 Эли Лилли Энд Компани Агонисты активируемых пероксисомальным пролифератором рецепторов
PL208074B1 (pl) * 2001-05-15 2011-03-31 Hoffmann La Roche Pochodne oksazolu, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie pochodnych oksazolu

Also Published As

Publication number Publication date
CA2445145C (en) 2008-10-14
ES2264482T3 (es) 2007-01-01
DE60211891T2 (de) 2007-05-24
PE20021152A1 (es) 2003-02-07
MXPA03010435A (es) 2004-03-09
KR20030096397A (ko) 2003-12-24
CY1105160T1 (el) 2009-11-04
PL208074B1 (pl) 2011-03-31
DE60211891D1 (de) 2006-07-06
AU2002342244B2 (en) 2005-06-16
NO20035086D0 (no) 2003-11-14
IL158589A (en) 2010-11-30
BRPI0209821B1 (pt) 2016-09-27
HRP20030889A2 (en) 2005-08-31
GT200200085A (es) 2003-01-16
ZA200308538B (en) 2005-04-26
ME01310B (me) 2011-10-10
BG66316B1 (bg) 2013-04-30
CZ20033037A3 (cs) 2004-06-16
CN100356917C (zh) 2007-12-26
ECSP034848A (es) 2003-12-24
PT1392295E (pt) 2006-09-29
BG108362A (bg) 2005-03-31
AR035892A1 (es) 2004-07-21
WO2002092084A1 (en) 2002-11-21
MA27025A1 (fr) 2004-12-20
US6642389B2 (en) 2003-11-04
HU230224B1 (hu) 2015-10-28
HRP20030889B1 (hr) 2011-10-31
JP2004529174A (ja) 2004-09-24
NZ529033A (en) 2005-06-24
ATE327753T1 (de) 2006-06-15
SK287842B6 (sk) 2011-12-05
US20030055265A1 (en) 2003-03-20
JP2009138011A (ja) 2009-06-25
SI1392295T1 (sl) 2006-10-31
HUP0400992A2 (hu) 2004-08-30
BR0209821A (pt) 2004-06-01
IL158589A0 (en) 2004-05-12
NO20035086L (no) 2003-11-14
HK1067534A1 (en) 2005-04-15
HUP0400992A3 (en) 2007-11-28
EP1392295A1 (en) 2004-03-03
CN1509173A (zh) 2004-06-30
KR100654516B1 (ko) 2006-12-05
RU2003134150A (ru) 2005-06-10
EP1392295B1 (en) 2006-05-31
EG25755A (en) 2012-06-26
PL367087A1 (en) 2005-02-21
RU2278859C2 (ru) 2006-06-27
NO333833B1 (no) 2013-09-30
JO2282B1 (en) 2005-09-12
PA8544901A1 (es) 2003-01-24
DK1392295T3 (da) 2006-10-02
CA2445145A1 (en) 2002-11-21
JP4330883B2 (ja) 2009-09-16
SK13852003A3 (en) 2004-10-05

Similar Documents

Publication Publication Date Title
JO2282B1 (en) Oxazole derivatives
MY135841A (en) Novel benzodioxoles
ATE384058T1 (de) Thiazolderivate
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
TW200500358A (en) Compounds
GB0413087D0 (en) Therapeutic compounds
EA200501936A1 (ru) Производные пиридо[2,1-a]изохинолина в качестве ингибиторов dpp-iv
TW200505881A (en) Tri(cyclo) substituted amide compounds
GB0318447D0 (en) Therapeutic agents
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
MXPA05014082A (es) Acidos biariloximetilarenocarboxilicos.
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
GB0112348D0 (en) Compounds
NO20072608L (no) Biaryloksymetylarenkarboksylsyrer
NO20082496L (no) Pyrazinderivater
EA200600223A1 (ru) Замещённый 2-аминотетралины для лечения депрессии
TW200740787A (en) (6-Fluoro-benzo[1,3]dioxolyl)-morpholin-4-yl-methanones
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
MX2007011695A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
TW200407133A (en) Novel PPARα and PPARγ agonists
MXPA05006889A (es) Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
MXPA04006041A (es) Antivirales de piridoquinoxalina.
MXPA05010020A (es) Derivados de oxamida.